- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00387010
Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain
A 4-week Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Pain
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35244
- Birmingham Pain Center
-
-
Arizona
-
Phoenix, Arizona, United States, 85023
- Arizona Research Center
-
-
California
-
Anaheim, California, United States, 92801
- Orange County Clinical Trials
-
Bakersfield, California, United States, 93311
- Vertex Clinical Research
-
Beverly Hills, California, United States, 90211
- Lovelace Scientific Resources, Inc.
-
National City, California, United States, 91950
- Synergy Clinical Research Center
-
Santa Monica, California, United States, 90404
- Pain Institute of Santa Monica
-
-
Colorado
-
Westminster, Colorado, United States, 80021
- Integrative Pain Manage Centers
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Advanced Diagnostic Pain Treatment Center
-
-
Florida
-
Clearwater, Florida, United States, 33761
- Alliance Medical Research Group
-
Largo, Florida, United States, 33770
- Innovative Research of West Florida
-
Sarasota, Florida, United States, 34233
- Lovelace Scientific Resources, Inc.
-
Tampa, Florida, United States, 33647
- Stedman Clinical Trials
-
-
Georgia
-
Dawsonville, Georgia, United States, 30534
- Dawsonville Family Medicine
-
-
Illinois
-
Bloomington, Illinois, United States, 61701
- Millennium Pain Center
-
Chicago, Illinois, United States, 60610
- Pain and Rehabilitation Clinic of Chicago
-
-
Indiana
-
Elkhart, Indiana, United States, 46514
- Elkhart Clinic, LLC
-
Indianapolis, Indiana, United States, 46250
- Rehabilitation Associates of Indiana
-
Valparaiso, Indiana, United States, 46383
- Northwest Indiana Center for Clinical Research, PC
-
-
Kansas
-
Overland Park, Kansas, United States, 66211
- ICRI, Inc.
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71103
- Willis-Knighton Pain Management Center
-
-
Montana
-
Missoula, Montana, United States, 59802
- Montana Cancer Specialists
-
-
Nevada
-
Henderson, Nevada, United States, 89014
- Lovelace Scientific Resources Center
-
Las Vegas, Nevada, United States, 89104
- Clinical Research Center of Nevada
-
-
New York
-
Stony Brook, New York, United States, 11794
- SUNY - Stonybrook
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- Pain Consultants of Oregon
-
-
Pennsylvania
-
Altoona, Pennsylvania, United States, 16602
- Allegheny Pain Management, PC
-
Duncansville, Pennsylvania, United States, 16635
- Altoona Center for Clinical Research
-
-
South Carolina
-
Greer, South Carolina, United States, 29651
- DeGarmo Institute of Medical Research
-
-
Tennessee
-
Hendersonville, Tennessee, United States, 37075
- Comprehensive Pain Specialists, PLLC
-
-
Texas
-
Richardson, Texas, United States, 75080
- KRK Medical Research
-
Richardson, Texas, United States, 75082
- Bexar Clinical Trials, LLC
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
- Lifetree Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient is willing to provide written informed consent to participate in this study.
- The patient is 18 through 80 years of age.
- Women must be surgically sterile, 2 years postmenopausal, or, if of childbearing potential, using a medically accepted method of birth control (i.e., barrier method with spermicide, steroidal contraceptive [oral, transdermal, implanted, and injected contraceptives must be used in conjunction with the barrier method], or intrauterine device [IUD]) and agree to continued use of this method for the duration of the study.
- The patient has chronic pain of at least 3 months duration associated with any of the following conditions: cancer, diabetic peripheral neuropathy, postherpetic neuralgia, traumatic injury, complex regional pain syndrome, back pain, neck pain, fibromyalgia (patient has met diagnostic criteria), chronic pancreatitis, or osteoarthritis. Other chronic painful conditions may be evaluated for entry upon discussion with and written approval from the Cephalon medical expert.
- The patient is currently using 1 of the following: at least 60 mg of oral morphine/day, or at least 25 mcg of transdermal fentanyl/hour, or at least 30 mg of oxycodone/day, or at least 8 mg of hydromorphone/day, or an equianalgesic dose of another opioid/day as a stable dose of around-the-clock (ATC) therapy for at least 7 days prior to enrollment in the study.
- The patient reports an average pain intensity score, over the prior 24 hours, of 6 or less (0=no pain through 10=worst pain) for the chronic pain.
- The patient experiences, on average, 1 to 4 BTP episodes per day while taking around-the-clock (ATC) opioid therapy, and on average, the duration of each breakthrough pain (BTP) episode is less than 3 hours.
- The patient currently uses opioid therapy for alleviation of BTP episodes occurring at the location of the chronic pain, and achieves at least partial relief.
- The patient must be willing and able to successfully self-administer the study drug, comply with study restrictions, and return to the clinic for scheduled study visits and a follow-up evaluation as specified in this protocol.
Exclusion Criteria:
- The patient has uncontrolled or rapidly escalating pain as determined by the investigator (ie, the ATC therapy may be expected to change between the first and last treatments with study drug), or has pain uncontrolled by therapy that could adversely impact the safety of the patient or that could be compromised by treatment with study drug.
- The patient has known or suspected hypersensitivities, allergies, or other contraindications to any ingredient in the study drug.
- The patient has a recent history (within 5 years) or current evidence of alcohol or other substance abuse.
- The patient has cardiopulmonary disease that, in the opinion of the investigator, would significantly increase the risk of treatment with potent synthetic opioids.
- The patient has medical or psychiatric disease that, in the opinion of the investigator, would compromise collected data.
- The patient's primary painful condition is headache, including migraine.
- The patient is expected to have surgery during the study, and it is anticipated that the surgery will alleviate the patient's pain.
- The patient has had therapy before study drug treatment that, in the opinion of the investigator, could alter pain or response to pain medication.
- The patient is pregnant or lactating.
- The patient has participated in a previous study with fentanyl buccal tablets.
- The patient has participated in a study involving an investigational drug in the previous 30 days.
- The patient has received a monoamine oxidase inhibitor (MAOI) within 14 days before the first treatment with study drug.
- The patient has any other medical condition or is receiving concomitant medication/therapy (e.g., regional nerve block) that, in the opinion of the investigator, would compromise the patient's safety or compliance with the study protocol, or compromise collected data.
- The patient is involved in active litigation in regard to chronic pain currently being treated.
- The patient has a positive urine drug screen (UDS) for an illicit substance or a medication not legitimately prescribed to the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: fentanyl buccal tablets
Successful dose strength for each participant was determined during a titration period of no more than 10 days.
Participants used the successful dose of 100, 200, 400, 600, or 800 mcg during the four week open-label treatment period.
|
Fentanyl buccal tablets (FBT) placed in the buccal cavity above a rear molar until disintegrated, approximately 14-25 minutes. Dose titration: Participants self-administered FBT, starting at 100, 200 or 400 mcg (depending on analgesic used pre-study) and titrated to 600 and 800 mcg as needed. For each breakthrough pain (BTP) episode, participants took a dose, and did not take further study drug if adequate pain relief was achieved. If pain was not controlled within 30 minutes, the same dose level was repeated. If pain relief was inadequate 30 minutes after the second dose, usual rescue medication was taken for that BTP episode. Doses were adjusted until pain relief was adequate and side effects were tolerated. Open-label: Once the successful dose of FBT was identified (100, 200, 400, 600, or 800 mcg), participants were dispensed a 4-week supply at the successful dose. Participants were not to use FBT for more than 6 BTP episodes or take more than 8 FBT daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the Pain Anxiety Symptoms Scale (PASS) Total Score at Approximately Week 5
Time Frame: Day 0 (baseline), approximately week 5
|
The change from baseline to approximately week 5 in the PASS total score.
PASS asks participants to indicate how often they engage in each of the 40 thoughts or activities that represent anxiety symptoms on a scale of 0=never to 5=always.
The total score has a range of 0-200.
|
Day 0 (baseline), approximately week 5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the Pain Anxiety Symptoms Scale (PASS) Subscale Scores at Approximately Week 5
Time Frame: Day 0 (baseline), approximately week 5
|
The change from baseline to approximately week 5 in the PASS subscale scores.
PASS asks participants to indicate how often they engage in each of the 40 thoughts or activities that represent anxiety symptoms on a scale of 0=never to 5=always.
Those 40 questions are organized into four subscales: fear, cognitive anxiety, somatic anxiety, and escape/avoidance.
Each subscale score is obtained by summing the answers to the ten items in the subscore resulting in a range of 0-50.
|
Day 0 (baseline), approximately week 5
|
Change From Baseline in the Beck Depression Inventory at Approximately Week 5
Time Frame: Day 0 (baseline), approximately week 5
|
Change from baseline to endpoint (week 4 of Treatment period or last post baseline visit) in the Beck Depression Inventory (BDI).
The BDI is a self-reporting instrument that asks 21 questions regarding how the participant felt in the past few days.
Answers are in sentence form, and offer a scale where the first answer (worth 0 points) indicates no depression and the fourth answer (worth 3 points) indicates significant depression.
Totals (0-63) are grouped so that totals of 1-10 are interpreted as 'These ups and downs are considered normal' and scores >40 indicate extreme depression.
|
Day 0 (baseline), approximately week 5
|
Change From Baseline in the West Haven-Yale Multidimensional Pain Inventory Subscales at Approximately Week 5
Time Frame: Day 0 (baseline), approximately week 5
|
Change from baseline to endpoint (week 4 of Treatment period or last post baseline visit) in the Multidimensional Pain Inventory Subscales.
Answers to questions in the MPI are captured on a 7-point scale, with 0=most positive answer and 6= least positive answer.
Twenty questions focus on pain, fourteen on a significant other's response when participant is in pain, and eighteen questions about daily activities.
There are a total of 13 subscales with variable ranges.
Subscales and corresponding ranges are listed in the results table.
The General Activity category combines the Household Chores, Outdoor Work, Activities Away from Home, and Social Activities categories.
|
Day 0 (baseline), approximately week 5
|
Medication Preference From the Pain Flare Treatment Satisfaction Questionnaire at Approximately Week 5
Time Frame: approximately week 5
|
The summary question from the Pain Flare Treatment Satisfaction Questionnaire asked participants which medication they preferred to use for their break-through pain.
Options were 1) Prior medication 2) Study medication 3) no preference
|
approximately week 5
|
Patient Assessment of Ability to Go to Work at Approximately Week 5
Time Frame: approximately week 5
|
At the endpoint of the study (week 4 of Treatment period or last post baseline visit) participants completed the Patient Assessment of Function Scale which asks 7 questions about the effect of study treatment on the patient's ability to function.
This question asks about the ability to go to work.
|
approximately week 5
|
Patient Assessment of Ability to Perform at Work at Approximately Week 5
Time Frame: approximately week 5
|
At the endpoint of the study (week 4 of Treatment period or last post baseline visit) participants completed the Patient Assessment of Function Scale which asks 7 questions about the effect of study treatment on the patient's ability to function.
This question asks about the ability to perform at work and includes both work outside the home and housework.
|
approximately week 5
|
Patient Assessment of Ability to Walk at Approximately Week 5
Time Frame: approximately week 5
|
At the endpoint of the study (week 4 of Treatment period or last post baseline visit) participants completed the Patient Assessment of Function Scale which asks 7 questions about the effect of study treatment on the patient's ability to function.
This question asks about the ability to walk.
|
approximately week 5
|
Patient Assessment of Ability to Exercise at Approximately Week 5
Time Frame: approximately week 5
|
At the endpoint of the study (week 4 of Treatment period or last post baseline visit) participants completed the Patient Assessment of Function Scale which asks 7 questions about the effect of study treatment on the patient's ability to function.
This question asks about the ability to exercise.
|
approximately week 5
|
Patient Assessment of Ability to Participate in Social Events at Approximately Week 5
Time Frame: approximately week 5
|
At the endpoint of the study (week 4 of Treatment period or last post baseline visit) participants completed the Patient Assessment of Function Scale which asks 7 questions about the effect of study treatment on the patient's ability to function.
This question asks about the ability to participate in social events.
|
approximately week 5
|
Patient Assessment of Ability to Have Sex at Approximately Week 5
Time Frame: approximately week 5
|
At the endpoint of the study (week 4 of Treatment period or last post baseline visit) participants completed the Patient Assessment of Function Scale which asks 7 questions about the effect of study treatment on the patient's ability to function.
This question asks about the ability to have sex.
|
approximately week 5
|
Patient Assessment of Ability to Enjoy Life at Approximately Week 5
Time Frame: approximately week 5
|
At the endpoint of the study (week 4 of Treatment period or last post baseline visit) participants completed the Patient Assessment of Function Scale which asks 7 questions about the effect of study treatment on the patient's ability to function.
This question asks about the ability to enjoy life.
|
approximately week 5
|
Clinical Assessment of Patient Function - General Activities - at Approximately Week 5
Time Frame: approximately week 5
|
At the endpoint of the study (week 4 of Treatment period or last post baseline visit) investigators completed the Clinical Assessment of Patient Function Scale which asks 5 questions about the effect of study treatment on the patient's ability to function.
This question asks about the patient's general activities.
|
approximately week 5
|
Clinical Assessment of Patient Function - Patient's Walking Ability - at Approximately Week 5
Time Frame: approximately week 5
|
At the endpoint of the study (week 4 of Treatment period or last post baseline visit) investigators completed the Clinical Assessment of Patient Function Scale which asks 5 questions about the effect of study treatment on the patient's ability to function.
This question asks about the patient's walking ability.
|
approximately week 5
|
Clinical Assessment of Patient Function - Patient's Ability to Work/Perform Activities of Daily Living - at Approximately Week 5
Time Frame: approximately week 5
|
At the endpoint of the study (week 4 of Treatment period or last post baseline visit) investigators completed the Clinical Assessment of Patient Function Scale which asks 5 questions about the effect of study treatment on the patient's ability to function.
This question asks about the patient's ability to work and perform activities of daily living.
|
approximately week 5
|
Clinical Assessment of Patient Function - Patient's Relationship With Others - at Approximately Week 5
Time Frame: approximately week 5
|
At the endpoint of the study (week 4 of Treatment period or last post baseline visit) investigators completed the Clinical Assessment of Patient Function Scale which asks 5 questions about the effect of study treatment on the patient's ability to function.
This question asks about the patient's relationship with others.
|
approximately week 5
|
Clinical Assessment of Patient Function - Patient's Enjoyment of Life - at Approximately Week 5
Time Frame: approximately week 5
|
At the endpoint of the study (week 4 of Treatment period or last post baseline visit) investigators completed the Clinical Assessment of Patient Function Scale which asks 5 questions about the effect of study treatment on the patient's ability to function.
This question asks about the patient's enjoyment of life.
|
approximately week 5
|
Summary of Participants' Successful Dosing Levels of Fentanyl Buccal Tablets to Control Episodes of Breakthrough Pain (BTP)
Time Frame: up to 10 days
|
During the dose titration period, participants self-administered FBT, starting at 100, 200 or 400 mcg (depending on analgesic used pre-study) and titrated to 600 and 800 mcg if needed.
For each breakthrough pain (BTP) episode, participants took a dose, and did not take further study drug if adequate pain relief was achieved.
If pain was not controlled within 30 minutes, the same dose level was repeated.
If pain relief was inadequate 30 minutes after the second dose, usual rescue medication was taken for that BTP episode.
Doses were adjusted until pain relief was adequate and side effects were tolerated.
This outcome summarizes the successful dose levels identified during the titration period.
|
up to 10 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Chronic Pain
- Breakthrough Pain
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Adjuvants, Anesthesia
- Fentanyl
Other Study ID Numbers
- C25608/3054/BP/US
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on Fentanyl Buccal Tablets
-
Cairo UniversityCompleted
-
Chang Gung Memorial HospitalTTY BiopharmCompletedBreakthrough Cancer PainTaiwan
-
CephalonCompleted
-
M.D. Anderson Cancer CenterTeva Pharmaceuticals USACompleted
-
Peking University People's HospitalCompletedGingivitis | Pharyngitis AcuteChina
-
BioDelivery Sciences InternationalCompletedRespiratory Depression
-
University of MinnesotaBaylor College of Medicine; University of California, San Diego; New York University and other collaboratorsTerminatedUrethral StrictureUnited States
-
Mackay Memorial HospitalCompleted
-
CephalonTerminatedBreakthrough Pain | Cancer PainSpain, Germany, France, Ireland, Italy, Poland, United Kingdom
-
Datar Cancer Genetics LimitedNational University of Singapore; Test At Home Pte. LtdNot yet recruiting